Search results
Results from the WOW.Com Content Network
Common side effects include hot flashes, unstable mood, trouble sleeping, headaches, and pain at the site of injection. [10] Other side effects may include high blood sugar, allergic reactions, and problems with the pituitary gland. [10] Use during pregnancy may harm foetal development. [10] Leuprorelin was patented in 1973 and approved for ...
Detomidine is an imidazole derivative and α 2-adrenergic agonist, [1] used as a large animal sedative, primarily used in horses. It is usually available as the salt detomidine hydrochloride. It is a prescription medication available to veterinarians sold under various trade names.
Flunixin is a nonsteroidal anti-inflammatory drug (NSAID), analgesic, and antipyretic used in horses, cattle and pigs. It is often formulated as the meglumine salt.In the United States, it is regulated by the U.S. Food and Drug Administration (FDA), and may only be lawfully distributed by order of a licensed veterinarian.
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
The injectable formulations of tylosin can cause pain, inflammation, and itchiness around the injection site. [ citation needed ] Since tylosin has a relatively poor spectrum of activity against Gram-negative organisms, it may not be a sensible therapeutic choice in the treatment of infections caused by unknown, potentially unsusceptible organisms.
Enjoy a classic game of Hearts and watch out for the Queen of Spades!
Pituitary pars intermedia dysfunction (PPID), or equine Cushing's disease, is an endocrine disease affecting the pituitary gland of horses. It is most commonly seen in older animals, [1] and is classically associated with the formation of a long, wavy coat and chronic laminitis.
Moxidectin was approved for onchocerciasis (river-blindness) in 2018 for people over the age of 11 in the United States based on two studies. [5] There is a need for additional trials, with long-term follow-up, to assess whether moxidectin is safe and effective for treatment of nematode infection in children and women of childbearing potential. [6]